Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Novo Nordisk A/S | Ocedurenone - (CLARION-CKD) | Chronic kidney disease | Phase 3 | Trial Discontinued | Oral | N/A |
| Novo Nordisk A/S | Etavopivat (FT-4202) - (HIBISCUS) | Thalassemia / sickle cell disease | Phase 2/3 | Ongoing | oral | Hematology |
| Novo Nordisk A/S | Efruxifermin - (HARMONY) | Nonalcoholic Steatohepatitis | Phase 2b | Data Released | Subcutaneous | Gastroenterology |
| Novo Nordisk A/S | Efruxifermin - (SYMMETRY) | Metabolic-associated steatohepatitis (MASH) | Phase 2b | Data Released | Subcutaneous | Gastroenterology |
| Novo Nordisk A/S | Etavopivat | Myelodysplastic syndromes (MDS) | Phase 2 | Trial Completed | Oral | Hematology |
| NovoCure Limited | Optune (EF-32) - (TRIDENT) | Glioblastoma Multiforme | Phase 3 | Enrollment Conclusion | Transdermal | Oncology |
| NovoCure Limited | Tumor Treating Fields (TTFields) - (PANOVA-4) | Metastatic pancreatic cancer | Phase 2 | Ongoing | Transdermal | Oncology |
| NovoCure Limited | Tumor Treating Fields (TTFields) with KEYTRUDA (pembrolizumab) - (KEYNOTE-B36) | Non-small cell lung cancer (NSCLC) | Phase 2 | Ongoing | TTFields: transducer arrays on the scalp KEYTRUDA: intravenous | Oncology |
